Patents Assigned to Merck
  • Arylalkylpyridazinones
    Publication number: 20020111356
    Abstract: Aralkylpyridazinone derivatives of the formula I 1
    Type: Application
    Filed: April 8, 2002
    Publication date: August 15, 2002
    Applicant: MERCK KGAA
    Inventors: Rochus Jonas, Michael Wolf, Norbert Beier
  • Pigment preparation with modified colophony resins
    Patent number: 6432195
    Abstract: The invention relates to a non-dusting, homogeneous pigment preparation which is distinguished by the fact that it comprises at least 40% by weight of one or more effect pigments and 0.5-59.5% by weight of a modified colophony resin, based on the pigment preparation, and the use thereof, in particular for the production of dry preparations. The pigment preparation according to the invention and the dry preparations produced therefrom are particularly suitable for the pigmenting of paints, coatings, powder coatings, printing inks and plastics.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: August 13, 2002
    Assignees: Merck Patent Gesellschaft mit beschraenkter Haftung, Lackharzwerke Robert Kraemer GmbH & Co.
    Inventors: Thomas Rathschlag, Carsten Griessmann, Sabine Schoen, Werner Sarfert
  • Polymorphic form of a tachykinin receptor antagonist
    Patent number: 6432952
    Abstract: This invention is concerned with a novel polymorphic forms of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)4-( 5-(dimethyl-amino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine hydrochloride which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic forms have advantages over the other known forms of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)4-( 5-(dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine hydrochloride in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: August 13, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Louis Crocker, Dongwei Cai, Jiang Wang
  • Cyclopentyl modulators of chemokine receptor activity
    Patent number: 6432981
    Abstract: The present invention is directed to compounds of the formula I: (wherein R1, R2, R3, R4, R5, R7, R8, X, n, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: August 13, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Paul E. Finke, Kerry A. Hilfiker, Jennifer L. Loebach, Malcolm Maccoss, Sander G. Mills, Dong-Ming Shen, Bryan Oates
  • 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
    Patent number: 6432976
    Abstract: Novel 3-substituted 8-aza-bicyclo[3.2.1]octanes (commonly known as “tropanes”) substituted in the 8-position are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: August 13, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Wayne Thompson, David A. Claremon, Peter M. Munson, Brian Phillips
  • Polymorphic form of a tachykinin receptor antagonist
    Patent number: 6432953
    Abstract: This invention is concerned with a novel polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)-ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic form has advantages over the other known forms of 2-(R)-(1-(R)-(3,1-bis(trifluoro-methyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: August 13, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Louis Crocker, James McCauley
  • USE OF TRIS (TRIFLUORO METHYLSULFONYL) METHANE, IN ADDITION TO ALKALINE METAL SALTS AND ALKALINE-EARTH METAL SALTS THEREOF AS CATALYSTS DURING C-C BONDING SYNTHESES AND THE NOVEL MG SALT OF TRIS (TRIFLUORO METHYLSULFONYL) METHANE
    Patent number: 6433227
    Abstract: Compounds are used as catalysts according to general formula (1) M+x(C(SO2CF3)3)x, whereby x is equal to 1 or 2; M represents one hydrogen or alkaline metal atom when x equals 1; and M represents one alkaline-earth metal atom when x equals 2. The invention also relates to a novel Mg compound of formula (1).
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: August 13, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Herwig Buchholz, Klaus-Dieter Franz, Herbert Mayr, Marcus-Alexander Funke, Andrea Zehetner
  • Method for inhibiting bone resorption
    Patent number: 6432932
    Abstract: Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: August 13, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Anastasia G. Daifotis, Arthur C. Santora, II, A. John Yates
  • Aliphatic amine substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents
    Patent number: 6432980
    Abstract: Trisubstituted pyrroles are antiprotozoal agents useful in the treatment and prevention of protozoal diseases in human and animals, including the control of coccidiosis in poultry.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: August 13, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Biftu, Danqing D. Feng, Gui-Bai Liang, Mitree M. Ponpipom, Xiaoxia Qian, Narindar Girotra, Michael H. Fischer, Matthew J. Wyvratt
  • Compositions and methods for inhibiting bone resorption
    Patent number: 6432931
    Abstract: The present invention relates to oral compositions and methods for inhibiting bone resoprtion in a mammal while counteracting the occurrence of potentially adverse gastrointestinal effects. The compositions useful herein comprise the combination of a pharmaceutically effective amount of a nitrogen-containing bisphosphonate or a pharmaceutically-acceptable salt thereof and a pharmaceutically effective amount of an isoprenoid compound.
    Type: Grant
    Filed: June 21, 1999
    Date of Patent: August 13, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Alfred A. Reszka, Edward S. Scolnick
  • Pigment in thin flakes and a method for manufacturing the same
    Patent number: 6432535
    Abstract: A pigment in thin flakes where spherical silica particles having an average particle size of 20-400 nm are adhered on the surface of a flaky substrate having an average particle size of 0.5-10 &mgr;m and then the said spherical silica particle-adhered surface of the flaky substrate adhered with spherical silica is further coated with ultrafine particles of titanium dioxide.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: August 13, 2002
    Assignee: Merck Patent Geseelschaft mit beschraenkter Haftung
    Inventors: Tamio Noguchi, Yukitaka Watanabe
  • Method of prevention of prostatic carcinoma with 17&bgr;-N-monosubstituted-carbamoyl-4-aza-5&agr;-androst-1-en-3-ones
    Patent number: 6432971
    Abstract: 17&bgr;-N-monosubstituted-carbamoyl-4-aza-5&agr;-androst-1-en-3-ones of the formula wherein R1 is selected from hydrogen, methyl and ethyl and R2 is a straight or branched chain alkyl, cycloalkyl, aralkyl of from 1-12 carbons, or monocyclic aryl optionally containing 1 or more lower alkyl substituents of 1-2 carbon atoms and/or 1 or more halogens, and R′, R″, R′″ are hydrogen or methyl are useful for the prevention of prostatic carcinoma.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: August 13, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Glenn J. Gormley, Elizabeth Stoner
  • Process for the preparation of vinylene carbonate, polyvinylene carbonate and the use thereof and the preparation of a lithium ion battery comprising said vinylene carbonate
    Publication number: 20020107407
    Abstract: The invention relates to a process for the preparation of vinylene carbonate of the formula (I) 1
    Type: Application
    Filed: April 4, 2002
    Publication date: August 8, 2002
    Applicant: Merck Patent GmbH
    Inventors: Bernhard Seifert, Sylvia Becker, Mark Neuschutz
  • Silver-colored luster pigment
    Publication number: 20020104461
    Abstract: The present invention relates to silver-colored luster pigments based on multiply coated platelet-shaped substrates, which has at least one layer sequence of TiO2, a colorless coating and another TiO2 layer. The pigment can optionally have an outer protective layer. These luster pigments are useful and to the use thereof in paints, coatings, printing inks, including security printing inks, plastics, ceramic materials, glasses, cosmetic formulations and for producing pigment preparations and dry product forms such as granules, chips, pellets and briquettes.
    Type: Application
    Filed: December 6, 2001
    Publication date: August 8, 2002
    Applicant: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Christoph Schmidt, Andrea Heyland, Claudia Fornoff, Hans-Dieter Bruckner
  • Liquid-crystal medium, and electro-optical liquid-crystal display
    Publication number: 20020104983
    Abstract: The present invention relates to liquid-crystalline media which comprise at least one compound of the formula I and at least one compound of the formula II 1
    Type: Application
    Filed: October 29, 2001
    Publication date: August 8, 2002
    Applicant: MERCK PATENTGESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Juliane Suermann, Bernhard Rieger
  • Topical bisphosphonates for prevention of bone resorption
    Publication number: 20020107228
    Abstract: Bisphosphonates inhibit bone resorption associated with periodonatal or orthopedic surgery when applied topically to the bone. A novel formulation for topical application contains a gelatin matrix which is soaked in a solution containing a bone absorption inhibiting effective amount of a bisphosphonate or a pharmaceutically acceptable salt.
    Type: Application
    Filed: March 27, 2002
    Publication date: August 8, 2002
    Applicant: Merck & Co., Inc
    Inventors: Itzhak Binderman, Avinoam Yaffe
  • Laser-markable plastics and their preparation and use
    Publication number: 20020107305
    Abstract: The invention relates to a laser-markable transparent or translucent plastics which comprise pearlescent pigments in combination with laser-sensitive pigments which themselves do not exhibit any pearlescent effect. The pigment combination considerably improves the scanner legibility of applied laser markings. The invention also relates to a process for preparing the plastics, to the use of the plastics for producing moldings, to moldings produced in this way, and generally to the use of a mixture made from pearlescent pigment and laser-sensitive pigment in laser-markable plastics, for improving the scanner legibility of laser markings applied to the plastics.
    Type: Application
    Filed: December 18, 2001
    Publication date: August 8, 2002
    Applicant: Merck Patent GmbH
    Inventor: Gerhard Edler
  • Histone deacetylase as target for antiprotozoal agents
    Patent number: 6428983
    Abstract: Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: August 6, 2002
    Assignee: Merck & Co.
    Inventors: Paula M. Dulski, Robert W. Myers, Anne M. Gumett, Sandra J. Rattray, Dennis M. Schmatz
  • Vapor-deposition material for the production of high-refractive-index optical layers, and process for the production of the vapor-deposition material
    Publication number: 20020102412
    Abstract: A vapor-deposition material for the production of high-refractive-index optical layers of titanium oxide, titanium and lanthanum oxide under reduced pressure comprising a sintered mixture having the composition TiOx+z*La2O3, where x=1.5 to 1.8 and z=10 to 65% by weight, based on the total weight of the mixture. The constituents of the mixture are in the range of 10 to 65% by weight of lanthanum oxide, 38 to 74% by weight of titanium oxide and 2 to 7% by weight of titanium.
    Type: Application
    Filed: December 28, 2001
    Publication date: August 1, 2002
    Applicant: MERCK KGAA
    Inventors: Uwe Anthes, Martin Friz
  • &agr; v integrin receptor antagonists
    Patent number: 6426353
    Abstract: The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: July 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Byron H. Arison, Donghui Cui, Mark E. Duggan, Wasyl Halczenko, John H. Hutchinson, Thomayant Prueksaritanont, Raju Subramanian, Xiaojun Fang